Segmentation by type classifies animal blood products into six distinct categories: whole blood, plasma, red blood cells (RBCs), platelets, cryoprecipitate, and serum. Whole blood, the least processed form, is primarily used for emergency transfusions in large‑animal veterinary practice and retains all cellular and plasma constituents, contributing a modest share of market value due to limited shelf life. Plasma, harvested by centrifugation, serves as the source material for fractionation into immunoglobulins, albumin, and clotting factors, and therefore commands a larger revenue share. RBCs are separated to provide oxygen‑carrying capacity for chronic anemia treatment, while platelets are concentrated for hemostatic support in surgical procedures. Cryoprecipitate, a fibrinogen‑rich fraction derived from frozen plasma, addresses specific coagulopathy cases and adds niche premium pricing. Serum, the cell‑free supernatant, is employed in diagnostic assays and as a growth supplement in cell culture, generating consistent demand from research laboratories. The relative contribution of each type reflects processing complexity, regulatory constraints, and end‑use intensity, collectively defining the market’s structural composition.
